Immuron (IMRN) FCF Margin (2016 - 2023)

Name: Immuron (IMRN) FCF Margin (2016 - 2023) | Business Quant
Creator: Business Quant

Immuron's quarterly FCF Margin came in at 55.38% in Q4 2023, up 99.7% quarter-over-quarter from 18207.18% in Q4 2020.

Immuron has reported FCF Margin for 6 years, with the latest figure at 55.38% in Q4 2023.

For the quarter ending Q4 2023, FCF Margin changed N/A year-over-year to 55.38%; the trailing twelve-month figure through Dec 2024 stood at 0.0% (up 8.0% YoY), and the FY2025 full-year result was 125.88%, down 595.0% from the prior year.
FCF Margin for Q4 2023 stood at 55.38%, up from 18207.18% in the prior quarter.
The five-year high for FCF Margin was 55.38% in Q4 2023, with the low at 18207.18% in Q4 2020.
Average FCF Margin over 3 years is 9434.87%, with a median of 10042.04% recorded in 2019.
Year-over-year, FCF Margin tumbled 999860 bps in 2019 and sank 816514 bps in 2020.
Tracing IMRN's FCF Margin over 3 years: stood at 10042.04% in 2019, then tumbled by 81 bps to 18207.18% in 2020, then jumped by 100 bps to 55.38% in 2023.
The last three FCF Margin figures came in at 55.38% (Q4 2023), 18207.18% (Q4 2020), and 10042.04% (Q4 2019), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-3.98%
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	43.35%
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	23.53%
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	4.17%
10	Immuron	1.27 Bn	1.27 Bn	-	-

Download Data 🔒